86 results about "Carcinomatoses" patented technology

An angiotensin II receptor antagonist and the use thereof for treating cancerous pain. Specifically, the present invention relates to a compound of formula (IV) or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopic label, metabolite or prodrug thereof, and the use thereof for treating cancerous pain, preferably cancerous ostalgia.

Disclosed herein are methods for profiling a cancerous tumor using a high-throughput sequencing technique.

Antibody molecules that specifically bind to LAG-3 are disclosed. The anti-LAG-3 antibody molecules can be used to treat, prevent and / or diagnose cancerous or infectious disorders.

Described herein are methods such as multi-omic methods for assessing a disease such as cancer. The multi-omic methods may integrate proteomic, transcriptomic, genomic, lipidomic, or metabolomic data. The method screening diseases or disease states. Also described herein are methods for screening for diseases or disease states from biological samples. The methods may include assessing whether a nodule, mass, or cyst is cancerous.

A method for a method for treatment of cholangiocarcinoma (CCA) with cold atmospheric plasma and Folfirinox. The method includes treating a patient having CCA with a low dosage FOLFIRINOX regimen, for example, 6.73 nM, giving the patient the low-dosage FOLFIRINOX regimen pre-operatively, surgically removing the cancerous tumor from the patient, continuing the low-dosage FOLFIRINOX treatment regimen intra-operatively, applying cold atmospheric plasma to the surgical margins surrounding the area in the patient from which the tumor was removed, and continuing the FOLFIRINOX post-operatively.

The present invention relates to an antibody or fragment thereof specifically binding to meningeosis carcinoma-specific antigen, such as DDX53, KIF3C, and AKR1A1, an anti-body or fragment thereof for use in the prophylaxis and / or treatment of cancer, preferably melanoma, further preferably melanoma with leptomeningeal spread, highly preferably melanoma with meningeosis carcinomatosa, a pharmaceutical composition comprising said antibody or fragment thereof, a nucleic acid encoding said antibody or fragment thereof, a vector comprising said nucleic acid, a prokaryotic or eukaryotic host cell comprising said vector, and to a method for the prophylaxis and / or treatment of cancer, preferably melanoma, further preferably melanoma with leptomeningeal spread, highly preferably melanoma with meningeosis carcinomatosa, in a living being, comprising the admin- istration of a prophylactically and / or therapeutically effective amount of said antibody or fragment thereof or said pharmaceutical composition.

Pharmaceutical compositions including one or more integrin activators capable of capable of improving the anti-cancer activity of nature t-cells, wherein the integrin activators target integrins including, but not limited to, α4β1, α4β7, α5β1, αLβ2 and / or αVβ3 improving binding to their respective ligands including, but not limited to, VCAM-1, fibronectin, MAdCAM-1, ICAM-1, ICAM-2, and / or vitronectin, wherein the compositions treat, ameliorate, and / or reduce symptoms of diseases, maladies, and cancers, and methods for making and using for preventing, treating, ameliorating, and / or reducing symptoms of cancerous tumors, cancerous solid tumors, other cancerous growth, and / or other cancerous.

Provided is a coordination compound represented by formula (I). Also provided is a pharmaceutical composition that can be used to treat cancers, including the coordination compound of formula (I) and a pharmaceutically acceptable carrier. Also provided are applications of the coordination compound in inhibiting cancer cell survival or proliferation, inhibiting cancer cell migration or invasion, and treating cancerous tumors in a subject in need.

Disclosed herein systems, processors, or computer-readable media configured with instructions to: receive transmission and / or reflection images of a tissue of a subject, wherein the images are generated from acoustic signals derived from acoustic waveforms transmitted through the tissue; provide a set of prognostic parameters associated with a user selected region of interest; wherein the set of prognostic parameters comprises sound propagation metrics characterizing sound propagation within a tissue; wherein the set of prognostic parameters corresponds to inputs into a tissue classifier model; wherein the set of prognostic parameters comprises a plurality of subsets of related feature groupings; and determine a type of tissue of the subject based on said plurality of subsets of related feature groupings using the classifier model, wherein the type of tissue is a cancerous tumor, a fibroadenoma, a cyst, a nonspecific benign mass, and an unidentifiable mass.

The invention provides an injection capable of treating various cancerous pains and postoperative pains and a preparation method of the injection, and relates to the technical field of pharmaceutical preparations. The preparation method comprises the following steps: filling nitrogen into water for injection at the temperature of 30-60 DEG C, sequentially adding sodium chloride, citric acid and sodium citrate according to a preparation amount, stirring to dissolve the sodium chloride, the citric acid and the sodium citrate, then adding butorphanol tartrate according to a preparation amount, and stirring until the butorphanol tartrate is completely dissolved for later use. According to the preparation method of the butorphinol tartrate injection provided by the invention, the technological parameters are accurately controlled, and the reference preparation prescription of the butorphinol tartrate injection does not need to be changed, so that the sterile guarantee level of the butorphinol tartrate injection can be improved, the increase of the impurity content can be effectively controlled, and the good stability of the butorphinol tartrate injection is ensured.

The present disclosure provides compositions and methods for distinguishing between non-cancerous, pre-cancerous, and cancerous conditions in the esophagus. In particular, the present disclosure provides compositions and methods for distinguishing non-dysplastic Barrett's esophagus (NDBE) samples from pre-cancerous (e.g., low-grade or high-grade dysplasia) and / or cancerous (e.g., esophageal adenocarcinoma) samples based on methylation status and / or DNA copy number abnormalities.

Provided herein are methods for treating a cholecystokinin (CCK) receptor-expressing cancerous tumor in a subject. The methods comprising administering to the subject an effective amount of a CCK receptor inhibitor and an effective amount of an immune checkpoint inhibitor, wherein the CCK receptor inhibitor inhibits one or more CCK receptors selected from the group consisting of a CCK-A receptor, a CCK-B receptor and a CCK-C receptor, and wherein the immune checkpoint inhibitor is a programmed cell death protein 1 (PD1) inhibitor or a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor.

Described herein are Methods, systems, compositions, and macromolecule complexes, for detecting, analyzing, evaluating, screening for, prognosing, diagnosing, and / or monitoring, pre-cancerous and cancerous conditions with abnormal cell growth in a patient, including patients having Minimal Residual Disease (MRD).

The invention relates to a salt and a crystal form of a polycyclic anaplastic lymphoma kinase inhibitor, a preparation method of the salt and the crystal form, a pharmaceutical composition containing the salt and the crystal form, and application of the salt and the crystal form or the pharmaceutical composition. Specifically, the invention relates to a salt and a crystal form of a compound 5-chloro-N4-(2-(isopropyl sulfonyl) phenyl)-N2-(7-methyl-8-(piperidine-4-yl)-2, 3-dihydrobenzo [b] [1, 4] dioxin-5-yl) pyrimidine-2, 4-diamine used as an anaplastic lymphoma kinase inhibitor, a preparation method of the salt and the crystal form, a pharmaceutical composition containing the salt and the crystal form, and a preparation method of the pharmaceutical composition. The invention also discloses application of the salt and the crystal form or the pharmaceutical composition in drugs for preventing and / or treating anaplastic lymphoma kinase mediated cancers or non-cancerous related diseases.

The present invention describes novel drug-carrying nanoparticles called bionanocarriers capable of modulating the cellular redox system and targeting the cancerous tumor.Specifically, the invention relates to a nanomedicine strategy for combating cancerous tumor cells, a strategy that aims to target the tumor, and consists of providing quercetin-linked magnetite nanoparticles (Q): (MNPs Q), and 3,5-dimaleylbenzoic acid-linked magnetite nanoparticles (A3'5DMB): (MNPs A3'5DMB)M; both types of nanoparticles were subsequently encapsulated with chitosan (Qs) and O-carboxymethyl chitosan (O-CMQs), functionalized with 11-mercaptoundecanoic acid (MUDA), and finally the anti-ABCC3 antibody was attached to the polymer phase, which was used as a selective driver of the delivery process of the encapsulated nanoparticles, thus carrying out the construction of the bionanocarriers: BNC-1: MNPs-Q-Ab; BNC-2: MNPs-a3'5DMB-Ab.Its manufacturing method and the tests of its biological functionality, its stability, the degradation of the encapsulation for the tumor microenvironment, the controlled release profile of the drugs Q and A3'5DMB, selective cell uptake, intracellular localization, cytotoxic effect on steroids of hepatocellular carcinoma cells with altered redox balance and induction of apoptosis, as well as its safety on normal cells, are described.

The invention provides a method for treating cancer using a coadministration strategy that combines local codelivery of a therapeutic agent and an intracellular penetration enhancing agent, and optionally in further combination with local administration of an immunotherapeutic agent, such as a cancer vaccine or NKT agonist. The invention also provides a method for treating cancer using an intracellular penetration enhancing agent. The methods of the invention aim to substantially kill and / or destroy the target tumor cells, as well as those cancerous cells that have metastasized to other parts of the body.

An ultrasound system for breast cancer screening scans a breast by rotating a dish-shaped template with one or more breast-facing recesses and a smoother nipple covering area about a center or rotation that is at the breast but is spaced from the nipple, to produce a multiplicity of radially oriented two-dimensional images, and speeds up assessment of the images by subjecting them to an artificial intelligence process that identifies likely abnormalities in the breast as volumes of interest (VOIs) and characterizes each VOI as benign, suggestive of a follow-up sooner than a normal interval, or likely cancerous, and computer-generates a report directing the patient accordingly, wherein the process includes comparing volumes of suspected abnormalities estimated from a current scan with volumes of corresponding regions of the breast from one or more previous scans.

The invention relates to activity levels for diffusive alpha-emitter radiation therapy. Disclosed herein is a method for treating a cancerous tumor by implanting in the cancerous tumor at least one diffusive alpha-emitter radiation therapy (DaRT) source having a suitable radon release rate and for a given duration, such that the source provides a cumulative activity of released radon per centimeter length of at least 10 megabeel (MBq) hours during a given duration. Optionally, the sources are implanted in the form of an array of sources, each source in the array being spaced from its adjacent source by no more than 4.5 mm.

A method for treating a noncancerous gynecological disorder comprising: administering to a patient an effective amount of composition comprising a cannabis extract comprising cannabidiol (CBD) wherein the composition is preferably administered in a mucosal form, such as intravaginally.

A method for treating a cancerous tumor by implanting at least one diffusing alpha-emitter radiotherapy (DaRT) source (21) having a suitable radon release rate and for a given duration in the cancerous tumor such that the source (21) provides a cumulative activity of released radon of at least 10 megabecquerel (MBq) hours per centimeter length during the given duration. Optionally, the source (21) is implanted in the form of an array (160) of sources (21) in which each source is spaced no more than 4.5 millimeters from its neighboring sources (21).

Described herein are methods, such as multiomics methods, for assessing diseases, such as cancer. The multi-omics method can integrate proteomic data, transcriptomic data, genomic data, lipidomic data, or metabonomic data. The method screens for a disease or a disease state. Also described herein are methods for screening a disease or a disease state from a biological sample. The method may include assessing whether a nodule, mass, or cyst is cancerous.

Systems, methods and devices for controlled sympathectomy procedures for neuromodulation in the treatment of subjects having neoplastic conditions are disclosed. Systems, methods, and devices for interventionally treating a cancerous tumor and cancer related pain are disclosed.

Biomarkers for treatment response and other outcomes in the treatment of lesions, such as cancerous tumors, are derived from routine clinical medical images, such as computed tomography (CT) and magnetic resonance imaging (MRI) scans, using radiomic machine learning techniques. The biomarkers are based, at least in part, on phenotypes derived from vessel morphology features descriptive of vasculature associated with a lesion shown in the medical images and may also include other radiomic and pathomic types of features. The biomarkers and phenotypes may be used at multiple points in the treatment process, and treatment decisions may be based on changes in radiomic features or phenotypes longitudinally through the course of treatment. The biomarkers and phenotypes may also be used in clinical trials, to establish trial parameters, patient enrollment, drug dosage, and other trial parameters.

The purpose of the present invention is to provide a prophylactic or therapeutic agent for cancer pain. The present invention provides a pharmaceutical composition for preventing or treating cancer pain, comprising a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. In the formula (I), m is an integer of 1-4; r1 is independently selected from a group consisting of a hydrogen atom, a halogen atom, a methyl group optionally substituted by 1-3 halogen atoms, a methoxy group optionally substituted by 1-3 halogen atoms, and a methylthio group optionally substituted by 1-3 halogen atoms.

This invention relates to the field of traditional Chinese medicine preparation technology, and particularly to a traditional Chinese medicine composition for treating cancer pain and numbness, as well as its preparation and application. This invention designs a traditional Chinese medicine composition for cancer pain and numbness, comprising: *Houttuynia cordata*, *Aconitum carmichaelii*, processed *Aconitum carmichaelii*, centipede, *Astragalus membranaceus*, *Ephedra sinica*, clove, frankincense, ephedra, menthol, and azone. The scientifically formulated combination of principal, assistant, and adjuvant herbs allows for multi-target action on both "cancer pain" (inflammation, compression, nerve infiltration) and "CIPN" (nerve damage), resulting in a superior analgesic effect, while also possessing anti-inflammatory, anti-swelling, potential tumor-suppressing, and nerve-repairing effects. The traditional Chinese medicine composition is prepared into a traditional Chinese medicine ointment, which is administered transdermally, allowing a high concentration of the drug to act directly on the lesion, avoiding the systemic side effects (addiction, constipation, etc.) associated with oral opioids. This is especially suitable for patients who cannot take oral opioids or cannot tolerate them.

The present invenon relates to the use of an-BMP4 anbodies in a method for inhibing, prevenng, and treang cancer metastasis in paents. An-BMP4 anbodies have been found to inhibit and even prevent cancer metastasis in paents. These anbodies have also been found to inhibit growth of cancerous metastac cells, thereby treang cancer metastasis.

The invention discloses a breast cancer wound cleaning device which comprises a breast nursing brace, a flushing device, an oxygen therapy device and a suction device, the breast nursing brace comprises a breast fixing support, and the breast fixing support comprises a containing chamber used for containing the breasts of a female patient and flushing solution; a plurality of flushing heads, oxygen therapy heads and suction heads are arranged on the inner wall of the containing chamber, the flushing heads are connected with the flushing device through pipelines, the oxygen therapy heads are connected with the oxygen therapy device through pipelines, and the suction heads are connected with the suction device through pipelines. The operation accords with the particularity of the breast cancer wound, the operation is convenient and fast, the use is convenient, the cleaning of the wound, the surrounding skin and the like during the wound dressing change of a breast cancer patient can be safely assisted, and tissue damage, bleeding and the like are avoided; healing of wounds is accelerated through traditional Chinese medicine bath, oxygen therapy and the like, and comfort and compliance of patients in use are improved.

In an example, one or more implanted tumor temperature sensors may be used in a method to determine an oncological status metric for a patient having one or more cancerous tumors. The tumor temperature measurements are collected, along with a type of cancer and one or more descriptors of a cancer treatment regimen, to calculate the oncological status metric. The oncological status metric is an indicator of cancer treatment efficacy in a patient and may be determined in part, by a programmed algorithm or trained machine learning model.

The disclosure is directed to novel solid-state forms of Compound 9 and pharmaceutically acceptable salts of Compound 9, compositions comprising the same, and methods of using the same, including use in treating cancer, hypoxia related pathologies, disorders leading to ischemia, and non-cancerous angiogenic diseases.

The subject invention provides organoarsenicals or salts thereof, compositions comprising an organoarsenical or a salt thereof, and methods of using the organoarsenicals or salts thereof, or compositions for inhibiting glutaminase and for treating cancers. Specifically, the subject invention provides methods of inhibiting glutaminase (e.g., KGA) catalytic activity in a cell, methods of treating cancer or a tumor via, for example, the inhibition of glutaminase activity, and methods of disrupting and / or inhibiting growth and proliferation of cancerous or tumorous cells.